A clinically applicable gene expression-based score predicts resistance to induction treatment in acute myeloid leukemia.
Christian Moser,Vindi Jurinovic,Vindi Jurinovic,Sabine Sagebiel-Kohler,Bianka Ksienzyk,Aarif M. N. Batcha,Annika Dufour,Stephanie Schneider,Maja Rothenberg-Thurley,Cristina Sauerland,Dennis Görlich,Wolfgang E. Berdel,Utz Krug,Ulrich Mansmann,Wolfgang Hiddemann,Jan Braess,Karsten Spiekermann,Philipp A. Greif,Sebastian Vosberg,Klaus H. Metzeler,Klaus H. Metzeler,Jörg Kumbrink,Tobias Herold +22 more
1
TL;DR: In this paper, the authors used 29 gene expression markers (PS29MRC) to predict resistant disease at initial diagnosis of acute myeloid leukemia (AML) with high accuracy.
read more
About: This article is published in Blood Advances. The article was published on 23 Nov 2021. and is currently open access.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction.
C. A. Ortiz Rojas,Diego A Pereira-Martins,Candy Bellido More,Dominique Sternadt,Isabel Weinhäuser,J. R. Hilberink,Juan L Coelho-Silva,Carolina Hassibe Thomé,Germano Aguiar Ferreira,Emanuele Ammatuna,Gerwin A. Huls,Peter J M Valk,Jan Jacob Schuringa,E. M. Rego +13 more
TL;DR: The 4-PI emerges as a robust and straightforward prognostic tool to improve survival prediction in AML patients and is demonstrated to be potential marker to reclassified patients from the intermediate ELN2017 category to the adverse category.
1
References
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber,Attilio Orazi,Robert P. Hasserjian,Jürgen Thiele,Michael J. Borowitz,Michelle M. Le Beau,Clara D. Bloomfield,Mario Cazzola,James W. Vardiman +8 more
TL;DR: The 2016 edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition.
9.4K
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner,Elihu H. Estey,David Grimwade,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Hervé Dombret,Benjamin L. Ebert,Pierre Fenaux,Richard A. Larson,Ross L. Levine,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Hwei-Fang Tien,Andrew H. Wei,Andrew H. Wei,Bob Löwenberg,Clara D. Bloomfield +22 more
TL;DR: An international panel to provide updated evidence- and expert opinion-based recommendations for diagnosis and management of acute myeloid leukemia in adults includes a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
5.3K
Controlling the false discovery rate in behavior genetics research
TL;DR: The False Discovery Rate (FDR) is the expected proportion of false discoveries among the discoveries, and controlling the FDR goes a long way towards controlling the increased error from multiplicity while losing less in the ability to discover real differences.
4.1K
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Courtney D. DiNardo,Brian A. Jonas,Vinod Pullarkat,Michael J. Thirman,Jacqueline S. Garcia,Andrew H. Wei,Marina Konopleva,Hartmut Döhner,Anthony Letai,Pierre Fenaux,Elizabeth A. Koller,Violaine Havelange,Brian Leber,Jordi Esteve,Jianxiang Wang,Vlatko Pejša,Roman Hájek,Kimmo Porkka,Árpád Illés,David Lavie,Roberto M. Lemoli,Kazuhito Yamamoto,Sung-Soo Yoon,Jun-Ho Jang,Su-Peng Yeh,Mehmet Turgut,Wan-Jen Hong,Ying Zhou,Jalaja Potluri,Keith W. Pratz +29 more
TL;DR: In previously untreated patients with confirmed AML who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received zsitidine alone.
1.9K
Related Papers (5)
Alessandra Cesano,Cheryl L. Willman,Kenneth J. Kopecky,Urte Gayko,Santosh Putta,Brent Louie,Matt Westfall,Norman Purvis,David C. Spellmeyer,Carol Marimpietri,Aileen Cohen,James Hackett,Jing Shi,Michael G. Walker,Zhuoxin Sun,Elisabeth Paietta,Martin S. Tallman,Larry D. Cripe,Susan K. Atwater,Frederick R. Appelbaum,Jerald P. Radich +20 more
Hailun Li,Fangxin Hong,Leo I. Gordon,Richard I. Fisher,Nancy L. Bartlett,Michael Crump,Randy D. Gascoyne,Henry N. Wagner,Patrick J. Stiff,Bruce D. Cheson,Douglas A. Stewart,Brad S. Kahl,Jonathan W. Friedberg,Kristie A. Blum,Thomas M. Habermann,Joseph Tuscano,Richard T. Hoppe,Sandra J. Horning,Ranjana H. Advani +18 more